Nephrogenic Systemic Fibrosis: Experimental Studies Confound Prevailing Theory of Free Gadolinium as a Causative Factor

Jakobsen, J.
August 2008
Acta Radiologica;Aug2008, Vol. 49 Issue 6, p616
Academic Journal
The article presents the author's comments on two recent studies which improve the understanding of the pathogenesis of nephrogenic systemic fibrosis (NSF). The author says that the studies present very impressive models. One study investigated the role of NSF and the role of gadolinium and/or depletion of endogenous metalas possible triggers for NSF. Other study involved patients who were diagnosed with GBCA-induced NSF and fibroblasts.


Related Articles

  • Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis. Bose, Chhanda; Megyesi, Judit K.; Shah, Sudhir V.; Hiatt, Kim M.; Hall, Kimberly A.; Karaduta, Oleg; Swaminathan, Sundararaman // PLoS ONE;8/25/2015, Vol. 10 Issue 8, p1 

    Nephrogenic systemic fibrosis is associated with gadolinium contrast exposure in patients with reduced kidney function and carries high morbidity and mortality. We have previously demonstrated that gadolinium contrast agents induce in vivo systemic iron mobilization and in vitro differentiation...

  • Gadolinium chloride.  // Reactions Weekly;9/4/2010, Issue 1317, p25 

    The article describes the case of a 63-year-old man with a history of multiple sclerosis who developed nephrogenic systemic fibrosis after being exposed to gadolinium chloride-based contrast medium.

  • Gadodiamide.  // Reactions Weekly;3/20/2010, Issue 1293, p26 

    The article describes the case of a 53-year-old man who developed gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis after taking gadiodiamide before a magnetic resonance imaging (MRI) scan.

  • Dynamic behaviors of vimentin induced by interaction with GlcNAc molecules. Komura, Kenta; Ise, Hirohiko; Akaike, Toshihiro // Glycobiology;Dec2012, Vol. 22 Issue 12, p1741 

    The cytoskeleton protein vimentin is dramatically altered following pathological events such as fibrosis and tumorigenesis. Vimentin binds to multivalent N-acetylglucosamine (GlcNAc) molecules at the cell surface and interacts with O-linked β-GlcNAc proteins. Moreover, dying cells can be...

  • Gadoversetamide.  // Reactions Weekly;3/9/2013, Issue 1443, p18 

    An abstract of the article "Gadolinium-induced NSF claim resolved in favor of plaintiff," by J. B. Ball Jr. and colleagues is presented.

  • Gadopentetic acid/gadoteridol.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p104 

    The article presents a case study of a woman who developed nephrogenic systemic fibrosis (NSF) after being treated with gadopentetic acid and gadoteridol.

  • Nephrogenic Systemic Fibrosis. Bucala, Richard // Current Rheumatology Reviews;2010, Vol. 6 Issue 3, p162 

    The author focuses on nephrogenic systemic fibrosis (NSF), a fibrosing disorder that affected patients with renal insufficiency and was characterized by a quick thickening and hardening of the skin of the extremities. He notes that an epidemiologic link between the use of gadolinium-based...

  • Nephrogenic Systemic Fibrosis: A Fibrosing Disorder Induced by Gadolinium Exposure. Bernstein, Elana J.; Kay, Jonathan // International Journal of Advances in Rheumatology;2011, Vol. 9 Issue 4, p123 

    Nephrogenic systemic fibrosis (NSF) is an iatrogenic fibrosing disorder that primarily affects patients with chronic kidney disease in the setting of exposure to gadolinium-based contrast agents. Patients with NSF develop progressive skin hardening, tethering, and hyperpigmentation,...

  • Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis--a research on adverse drug events and reports (RADAR) report. EDWARDS, B. J.; LAUMANN, A. E.; NARDONE, B.; MILLER, F. H.; RESTAINO, J.; RAISCH, D. W.; MCKOY, J. M.; HAMMEL, J. A.; BHATT, K.; BAUER, K.; SAMARAS, A. T.; FISHER, M. J.; BULL, C.; SADDLETON, E.; BELKNAP, S. M.; THOMSEN, H. S.; KANAL, E.; COWPER, S. E.; ABU ALFA, A. K.; WEST, D. P. // British Journal of Radiology;Oct2014, Vol. 87 Issue 1042, p1 

    Objective: To compare and contrast three databases, that is, The International Centre for Nephrogenic Systemic Fibrosis Registry (ICNSFR), the Food and Drug Administration Adverse Event Reporting System (FAERS) and a legal data set, through pharmacovigilance and to evaluate international...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics